Clinical Trials Directory
Recruiting
Conditions
Sponsors
Search
About
Trials
/
Conditions
/ Neoplasms, Ovarian
Neoplasms, Ovarian
16 registered clinical trials studyying Neoplasms, Ovarian.
Status
Trial
Sponsor
Phase
Completed
A Study of MORAb-202 Versus Investigator's Choice Chemotherapy in Female Participants With Platinum-resistant
NCT05613088
Bristol-Myers Squibb
Phase 2
Unknown
Efficacy and Safety of Involving Field Radiotherapy in the Oligo-lesions(Metastasis/Recurrent/Refractory) of O
NCT05059782
Xi'an Jiaotong University
N/A
Completed
Study of ESG401 in Adults With Solid Tumors
NCT04892342
Shanghai Escugen Biotechnology Co., Ltd
Phase 1 / Phase 2
Unknown
Urinary Human Papilloma Virus Test in the General Population in Brittany
NCT03598946
University Hospital, Brest
N/A
Terminated
The Safety and Antitumor Activity of the Combination of Oregovomab and Hiltonol in Recurrent Advanced Ovarian
NCT03162562
CanariaBio Inc.
Phase 1
Completed
MRI-Guided Stereotactic Body Radiation Therapy (SBRT) for Ovarian Cancer
NCT02582931
Washington University School of Medicine
Phase 1
Terminated
Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer Plus Intranodal DC Vaccines
NCT02432378
Roswell Park Cancer Institute
Phase 1 / Phase 2
Terminated
PAZOFOS: Phase Ib and Phase II Trial of Pazopanib +/- Fosbretabulin in Advanced Recurrent Ovarian Cancer
NCT02055690
The Christie NHS Foundation Trust
Phase 1 / Phase 2
Completed
Safety and Effectivity Immunotherapy to Treat Ovarian Cancer With Cancer Stem Cells Vaccine
NCT02178670
Fuda Cancer Hospital, Guangzhou
Phase 1 / Phase 2
Completed
A Pivotal Bioequivalence Study of DOXIL/CAELYX (Doxorubicin HCL) in Patients With Advanced or Refractory Solid
NCT01815294
Janssen Research & Development, LLC
Phase 1
Completed
Efficacy and Safety of Pazopanib Monotherapy After First-line Chemotherapy in Ovarian, Fallopian Tube, or Prim
NCT01227928
GlaxoSmithKline
Phase 2
Completed
Combination Study Of SB-485232 (Interleukin 18) And Doxil For Advanced Stage Epithelial Ovarian Cancer
NCT00659178
GlaxoSmithKline
Phase 1
Completed
Feasibility Study of Pazopanib in Combination With Chemotherapy in Gynaecological Tumors
NCT00561795
GlaxoSmithKline
Phase 2
Completed
A Phase II, Open-Label Study Evaluating the Effect Of GW786034 In Subjects With Ovarian Cancer
NCT00281632
GlaxoSmithKline
Phase 2
Completed
Second-Line Therapy Study For Potentially Platinum-Sensitive Relapsed Ovarian Cancer
NCT00316173
GlaxoSmithKline
Phase 2
Completed
Second-line Intravenous Treatment For Recurrent Platinum-Sensitive Ovarian, Fallopian, Or Peritoneal Cancer
NCT00061308
GlaxoSmithKline
Phase 2